Akeso's (HKG:9926) ivonescimab drug showed strong positive results in a phase 3 trial in China for advanced squamous non-small cell lung cancer, according to a Wednesday filing with the Hong Kong bourse.
The drug also met the primary endpoint of progression-free survival and a favorable safety profile in a trial with 532 enrollees, the filing said.
The trial assessed the capabilities of ivonescimab plus chemotherapy against tislelizumab plus chemotherapy for the treatment of locally advanced or metastatic squamous non-small cell lung cancer, the filing said.
Shares in the drug company nearly 5% during afternoon trading on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。